SAN DIEGO, CA, USA I April 15, 2025 I Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new ...

Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid ...

They found that fat, gastrointestinal, liver, pancreatic, muscle, and lung cells all have CB1 receptors, it’s the blockade of these that is believed to be responsible for the therapeutic ...

A study published in Nature Neuroscience suggests that the cannabinoid receptor type 1 (CB1) could play a role in regulating stress responses by maintaining vascular integrity in the brain. The ...

THC binds to the CB1 receptor, found in the brain, but also in the myocardium, vascular endothelial, and smooth muscle cells. The CB1 receptor promotes atherosclerotic changes, Chandy explained ...

Agonists of the type 1 cannabinoid receptor (CB1) show promise as alternative analgesics but are still limited by side effects and tolerance. Reporting in Nature, Rangari et al. apply computation ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...

where the cannabinoid CB1 receptor is the most widely expressed G protein-coupled receptor in the CNS, although its presence is also high in peripheral tissues.